Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib

被引：0
|
作者：
Yu, Helena Alexandra
Kerr, Keith
Rolfo, Christian Diego
Fang, Jian
Finocchiaro, Giovanna
Wong, Kam-Hung
Veillon, Remi
Kato, Terufumi
Yang, James Chih-Hsin
Nadal, Ernest
Raskin, Jo
Le, Xiuning
Karachaliou, Niki
Ellers-Lenz, Barbara
OBrate, Aurora
Stroh, Christopher
Piske, Nadine
Boesler, Carsten
Yang, Jinji
Mazieres, Julien
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen, Scotland
[3] Aberdeen Royal Infirm, Aberdeen, Scotland
[4] Mt Sinai Med Syst, Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA
[5] Icahn Sch Med, New York, NY USA
[6] Peking Univ Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[7] IRCCS Humanitas Res Hosp, Milan, Italy
[8] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[9] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[10] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[11] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[12] Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain
[13] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[14] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[15] Merck KGaA, Healthcare Business, Global Clin Dev, Darmstadt, Germany
[16] Merck KGaA, Healthcare Business, Dept Biostat, Darmstadt, Germany
[17] Merck KGaA, Healthcare Business, Global Med Affairs, Darmstadt, Germany
[18] Merck KGaA, Healthcare Business, Compan Diagnost & Biomarker Strategy, Darmstadt, Germany
[19] Merck KGaA, Healthcare Business, Clin Biomarkers & Technol, Darmstadt, Germany
[20] Guangdong Gen Hosp & Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China
[21] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9074
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [42] COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
    Sequist, L. V.
    Peled, N.
    Tufman, A.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1101
  • [43] COMPEL: Chemotherapy with/without Osimertinib in Patients with EGFRm advanced NSCLC and Progression on first-line Osimertinib
    Tufman, Autoren A.
    Sequist, L.
    Peled, N.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    de Wit, M.
    PNEUMOLOGIE, 2023, 77 : S8 - S8
  • [44] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [45] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
  • [46] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [47] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [48] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
    Yu, Y.
    Yang, N.
    Zhang, Y.
    Zhang, H.
    Li, M.
    Yu, Q.
    Zhou, J.
    Hu, X.
    Fang, J.
    Zhao, H.
    Feng, J.
    Li, L.
    Shu, Y.
    Wang, X.
    Sun, M.
    Zhang, J.
    Li, M.
    Ren, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [49] First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
    Lorenzi, M.
    Dal Maso, A.
    Ferro, A.
    Polo, V.
    Scattolin, D.
    Macerelli, M.
    Follador, A.
    Targato, G.
    Indraccolo, S.
    Frega, S.
    Menis, J.
    Bonanno, L.
    Guarneri, V.
    Conte, P. F.
    Pasello, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S779
  • [50] Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report
    Gonzalez-Espinoza, I. R.
    Sanchez-Sosa, S.
    Castro-Ponce, A.
    Penaloza-Coronas, C.
    Montilla-Fonseca, S.
    Cuauro-Ruiz, G.
    Juarez-Salazar, D. A.
    Chiquillo-Dominguez, M.
    Juarez-Salazar, G.
    Gonzalez-Blanco, M. D. J.
    Aguilar-Priego, J. M.
    Cordero-Vargas, C.
    Miguel-Cruz, E.
    Montiel-Castro, J. S.
    Nieva-Silva, A. I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S672 - S672
12345